Short Interest in Seelos Therapeutics, Inc. (NASDAQ:SEEL) Decreases By 69.3%

Seelos Therapeutics, Inc. (NASDAQ:SEEL) saw a large decrease in short interest in October. As of October 15th, there was short interest totalling 52,500 shares, a decrease of 69.3% from the September 30th total of 170,900 shares. Based on an average daily trading volume, of 558,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 4.7% of the company’s shares are sold short.

Hedge Funds Weigh In On Seelos Therapeutics

A hedge fund recently raised its stake in Seelos Therapeutics stock. Gendell Jeffrey L lifted its holdings in shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 284.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 428,966 shares of the company’s stock after purchasing an additional 317,351 shares during the quarter. Gendell Jeffrey L owned about 2.58% of Seelos Therapeutics worth $254,000 as of its most recent filing with the Securities and Exchange Commission. 23.37% of the stock is currently owned by institutional investors and hedge funds.

Seelos Therapeutics Stock Up 3.4 %

NASDAQ:SEEL traded up $0.04 during trading hours on Friday, hitting $1.22. The company had a trading volume of 14,985 shares, compared to its average volume of 186,307. The company has a 50-day moving average of $3.38 and a 200 day moving average of $14.77. Seelos Therapeutics has a 1 year low of $0.82 and a 1 year high of $837.12.

Seelos Therapeutics (NASDAQ:SEEL) last issued its earnings results on Wednesday, August 14th. The company reported $1.92 earnings per share (EPS) for the quarter. The company had revenue of $0.38 million during the quarter.

About Seelos Therapeutics

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).